{"id":"daptomycin-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated creatine phosphokinase (CPK)"},{"rate":null,"effect":"Muscle pain or myopathy"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes in a calcium-dependent manner. It inserts into the lipid bilayer and causes rapid depolarization of the membrane potential, leading to leakage of intracellular potassium and other essential ions, ultimately resulting in bacterial cell death. This mechanism is bactericidal and effective against Gram-positive bacteria.","oneSentence":"Daptomycin disrupts bacterial cell membrane integrity by inserting into the lipid bilayer and causing depolarization and potassium efflux, leading to bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:13.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria"},{"name":"Staphylococcus aureus bacteremia including right-sided endocarditis"}]},"trialDetails":[{"nctId":"NCT06637332","phase":"PHASE4","title":"Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2024-11-14","conditions":"Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia","enrollment":300},{"nctId":"NCT03643952","phase":"PHASE2","title":"Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-06","conditions":"Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious","enrollment":18},{"nctId":"NCT00638157","phase":"PHASE4","title":"Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-02-13","conditions":"Infective Endocarditis","enrollment":24},{"nctId":"NCT04277143","phase":"","title":"A Pharmacokinetics Study of Daptomycin in Critically Ill Patients and Effects of Daptomycin on Kidney","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2020-12-01","conditions":"Outcome, Fatal, Infection","enrollment":120},{"nctId":"NCT00695903","phase":"PHASE2","title":"Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-09-17","conditions":"Endocarditis, Bacterial, Infective Endocarditis","enrollment":38},{"nctId":"NCT00711802","phase":"PHASE4","title":"Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2008-07-23","conditions":"Skin Diseases, Infectious","enrollment":396},{"nctId":"NCT00295178","phase":"PHASE4","title":"Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2006-02-20","conditions":"Cellulitis","enrollment":80},{"nctId":"NCT00651131","phase":"PHASE4","title":"Cubicin(R) for Complicated Post-surgical Wound Infections","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2004-06-01","conditions":"Wound Infections","enrollment":69},{"nctId":"NCT02508350","phase":"NA","title":"The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2015-01","conditions":"Septic Shock","enrollment":12},{"nctId":"NCT00463801","phase":"PHASE4","title":"Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-01","conditions":"Staphylococcal Skin Infections","enrollment":52},{"nctId":"NCT00858325","phase":"PHASE1","title":"Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-3009"],"phase":"marketed","status":"active","brandName":"Daptomycin for Injection","genericName":"Daptomycin for Injection","companyName":"Todd C. Lee MD MPH FIDSA","companyId":"todd-c-lee-md-mph-fidsa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daptomycin disrupts bacterial cell membrane integrity by inserting into the lipid bilayer and causing depolarization and potassium efflux, leading to bacterial cell death. Used for Complicated skin and soft tissue infections caused by susceptible Gram-positive bacteria, Staphylococcus aureus bacteremia including right-sided endocarditis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}